Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01530 3SBIO
RTNominal up6.080 +0.030 (+0.496%)
Others

19/09/2019 15:14

3SBio (01530) drug gets clinical trials approval

[ET Net News Agency, 19 September 2019] 3SBio Inc. (01530) said the clinical trial
application of the group's oral disintegration tablet of nalfurafine hydrochloride (the
TRK820), a drug to treat the pruritus of hemodialysis patients, has been approved by the
National Medical Products Administration to conduct clinical trials.
The soft capsule dosage-form of the TRK-820 has been sold in Japan since 2009 to treat
hemodialysis-related uremic pruritus (which is used only when sufficient efficacy of the
existing therapies or treatments is not achieved). (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 12:01
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.